Exscientia has the potential to be a star collaborator and a profitable drug developer, too.
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.
The high cost of developing drugs makes the use of artificial intelligence a natural fit for pharmaceutical companies.
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
Investors continue to look for stocks to buy as inflation cools. As you prepare for another busy week, here are some of our top stories from this week
A growing number of companies in the biotech and healthcare industries are using AI to revolutionize drug discovery and patient care, leading to stock surges.
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion
The company may be riding the wave of an AI healthcare boom.
The company benefited from a surge in interest in AI-associated stocks.
With a white-hot technology as a foundation for its business, the biotech's better-than-expected first-quarter results brought about a bull stampede.